Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event

Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event.

AstraZeneca was interested in knowing how Cardiologists and Physicians treat patients who have suffered a cardiovascular event.

Study Overview

• Status: Completed
• Conditions: Cardiovascular Events

• Study Type: Observational
• Enrollment (Actual): 88

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients with cardiovascular events

Description

Inclusion Criteria:

• All patients who has experienced cardiovascular events

Exclusion Criteria:

• Patients with no cardiovascular events.

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: AstraZeneca

Study record dates

Study Major Dates

• Study Start: January 1, 2010
• Primary Completion (Actual): July 1, 2010
• Study Completion (Actual): July 1, 2010

Study Registration Dates

• First Submitted: June 14, 2011
• First Submitted That Met QC Criteria: July 14, 2011
• First Posted (Estimate): July 15, 2011

Study Record Updates

• Last Update Posted (Estimate): August 30, 2011
• Last Update Submitted That Met QC Criteria: August 29, 2011
• Last Verified: August 1, 2011

More Information

Terms related to this study

• Other Study ID Numbers: NIS-CZA-XXX-2011/1